Global Guillain-Barré Syndrome Treatment Market 2019-2023 | Recent Approvals of immunoglobulins to Boost Demand | Technavio
LONDON--(BUSINESS WIRE)--Nov 20, 2018-- analysts forecast the global Guillain-Barré syndrome treatment market to grow at a CAGR of over 5 % during the forecast period, according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005258/en/
Technavio analysts forecast the global Guillain-Barre syndrome treatment market to grow at a CAGR of over 5% by 2023. (Graphic: Business Wire)
Strategic alliances is one of the major trends being witnessed in the . Pharmaceuticals companies are working together for the development of medications for the treatment of Guillain-Barré syndrome. These alliances will enhance the R&D activities of new drugs and will help companies develop drugs to treat and manage the syndrome, so that it can be introduced quickly into the market. Thus, such strategic alliances are expected to support the growth of the global Guillain-Barré syndrome treatment market during the forecast period.
According to Technavio analysts, one of the key factors contributing to the growth of the global Guillain-Barré syndrome treatment market is the recent approvals of immunoglobulins:
Global Guillain-Barré syndrome treatment market: Recent approvals of immunoglobulins
Immunoglobulins are the first-line treatment for Guillain-Barré syndrome. The recently approved immunoglobulins such as PANZYGA, Privigen, and Kenketu Glovenin-I are expected to generate significant revenue, which will drive the growth of the global Guillain-Barré syndrome treatment market during the forecast period.
According to a senior analyst at Technavio for research on infectious and rare diseases, “In August 2018, Octapharma received approval from Health Canada for PANZYGA, an immunoglobulin developed for the treatment of patients with moderate to severe Guillain-Barré syndrome. Similarly, in September 2017, CSL announced that the US FDA approved Privigen, an immunoglobulin developed for the treatment of adults with chronic Guillain-Barré syndrome.”
Global Guillain-Barré syndrome treatment market: Segmentation analysis
The global Guillain-Barré syndrome treatment market research report provides market segmentation by product (immunoglobulins and other therapeutics) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
The Americas held the largest share of the market in 2018, accounting for more than 40% share. It was followed by EMEA and APAC respectively. The rising incidence of Guillain-Barré syndrome in the leading countries of the region indicates the strong growth prospects of the market in the Americas.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005258/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL FDA
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 11/20/2018 11:48 AM/DISC: 11/20/2018 11:48 AM